Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

Modern Pathology

Volumn 28, Issue 5, 2015, Pages 706-714

  Ohgami, Robert S ^a   Ma, Lisa ^a   Merker, Jason D ^a   Gotlib, Jason R ^a   Schrijver, Iris ^a   Zehnder, James L ^a   Arber, Daniel A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; NUCLEOPHOSMIN; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; ASXL1 PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN; RIBONUCLEOPROTEIN; SPLICING FACTOR U2AF; TET2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER; U2AF1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASXL1 GENE; CEBPA GENE; CHILD; CSF3R GENE; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE MUTATION; HUMAN; INDEL MUTATION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; NRAS GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SETBP1 GENE; SF3B1 GENE; SRSF2 GENE; TET2 GENE; U2AF1 GENE; ACUTE MYELOID LEUKEMIA; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CHILD; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RIBONUCLEOPROTEINS; SPLICING FACTOR U2AF; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84928825295     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.160     Document Type: Article

References (46)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951
2. Visser O, Trama A, Maynadie M, et al. RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012; 48: 3257-3266
3. Sant M, Allemani C, Tereanu C, et al. HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116: 3724-3734
4. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006; 107: 2099-2107
5. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer: Lyon, France; 2008, p 439
6. Grimwade D, Hills RK, Moorman AV, et al. National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united kingdom medical research council trials. Blood. 2010; 116: 354-365
7. Dohner H, Estey EH, Amadori S, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-474
8. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011; 118: 5593-5603
9. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150: 264-278
10. Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010; 10: 401 2407-10-401
11. Ley TJ, Ding L,Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-2433
12. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43: 309-315
13. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012; 119: 3578-3584
14. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011; 2011: 208-214
15. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012; 26: 475-480
16. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012; 51: 743-755
17. Fernandez-Mercado M, Yip BH, Pellagatti A, et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One. 2012; 7: e42334
18. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010; 28: 3858-3865
19. Papaemmanuil E, Gerstung M, Malcovati L, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122: 3616-3627; quiz 3699
20. Chen TC, Hou HA, Chou WC, et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J 2014; 4: e177
21. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059-2074
22. National comprehensive cancer network. NCCN clinical practice guidelines in oncology: acute myeloid leukemia. www.nccn.org/professionals/physician-gls/pdf/aml.pdf
23. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333
24. Ohgami RS, Ohgami JK, Pereira IT, et al. Refining the diagnosis of T-cell large granular lymphocytic leukemia by combining distinct patterns of antigen expression with T-cell clonality studies. Leukemia. 2011; 25: 1439-1443
25. Spencer DH, Abel HJ, Lockwood CM, et al. Detection of FLT3 internal tandem duplication in targeted, shortread-length, next-generation sequencing data. J Mol Diagn. 2013; 15: 81-93
26. Ohgami RS, Ma L, Ren L, et al. DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. Br J Haematol. 2012; 159: 182-190
27. Weinberg OK, Ohgami RS, Ma L, et al. Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. Am J Clin Pathol. 2014; 142: 190-195
28. Reich M, Liefeld T, Gould J, et al. GenePattern 2.0. Nat Genet. 2006; 38: 500-501
29. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 2007; 7: 165-168
30. Muller PA, Vousden KH. P53 mutations in cancer. Nat Cell Biol. 2013; 15: 2-8
31. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012; 119: 2114-2121
32. Kihara R, Nagata Y, Kiyoi H, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014; 28: 1586-1595
33. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011; 44: 53-57
34. Qian J, Yao DM, Lin J, et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2012; 7: e45760
35. Yoshida K, Ogawa S. Splicing factor mutations and cancer. Wiley Interdiscip Rev RNA. 2014; 5: 445-459
36. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-1089
37. Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011; 118: 3803-3810
38. Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012; 5: 8722-5-12
39. Schuettengruber B, Chourrout D, Vervoort M, et al. Genome regulation by polycomb and trithorax proteins. Cell. 2007; 128: 735-745
40. Schwartz YB, Kahn TG, Stenberg P, et al. Alternative epigenetic chromatin states of polycomb target genes. PLoS Genet. 2010; 6: e1000805
41. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet. 2007; 8: 9-22
42. Muller J, Verrijzer P. Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr Opin Genet Dev. 2009; 19: 150-158
43. Abdel-Wahab O, Gao J, Adli M, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013; 210: 2641-2659
44. Fisher CL, Pineault N, Brookes C, et al. Loss-offunction additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood. 2010; 115: 38-46
45. Wrighton KH. Chromatin: TET2 keeps histones sweet. Nat Rev Mol Cell Biol. 2013; 14: 64-65
46. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011; 118: 4509-4518